Seilern Investment Management Ltd Has $85.77 Million Stock Position in West Pharmaceutical Services, Inc. $WST

Seilern Investment Management Ltd lowered its holdings in West Pharmaceutical Services, Inc. (NYSE:WST) by 24.2% in the 3rd quarter, HoldingsChannel reports. The institutional investor owned 326,957 shares of the medical instruments supplier’s stock after selling 104,604 shares during the period. West Pharmaceutical Services accounts for approximately 6.3% of Seilern Investment Management Ltd’s investment portfolio, making the stock its 7th biggest holding. Seilern Investment Management Ltd’s holdings in West Pharmaceutical Services were worth $85,771,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. Dynamic Technology Lab Private Ltd bought a new position in West Pharmaceutical Services in the 1st quarter worth $329,000. Amundi boosted its stake in shares of West Pharmaceutical Services by 83.4% during the 2nd quarter. Amundi now owns 502,831 shares of the medical instruments supplier’s stock valued at $111,236,000 after purchasing an additional 228,696 shares in the last quarter. Polar Asset Management Partners Inc. increased its position in shares of West Pharmaceutical Services by 106.5% during the first quarter. Polar Asset Management Partners Inc. now owns 53,070 shares of the medical instruments supplier’s stock valued at $11,881,000 after buying an additional 27,370 shares during the period. Sivik Global Healthcare LLC raised its stake in West Pharmaceutical Services by 20.0% in the second quarter. Sivik Global Healthcare LLC now owns 15,000 shares of the medical instruments supplier’s stock worth $3,282,000 after buying an additional 2,500 shares in the last quarter. Finally, Caxton Associates LLP purchased a new stake in West Pharmaceutical Services in the second quarter worth about $1,610,000. 93.90% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on WST. Redburn Partners set a $311.00 target price on West Pharmaceutical Services in a report on Monday, September 15th. Wall Street Zen upgraded West Pharmaceutical Services from a “hold” rating to a “buy” rating in a research report on Saturday. KeyCorp increased their price objective on West Pharmaceutical Services from $325.00 to $350.00 and gave the stock an “overweight” rating in a report on Friday, October 24th. TD Cowen began coverage on West Pharmaceutical Services in a research report on Wednesday, October 29th. They set a “buy” rating and a $350.00 price objective for the company. Finally, Rothschild & Co Redburn initiated coverage on shares of West Pharmaceutical Services in a report on Monday, September 15th. They set a “buy” rating and a $311.00 target price on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $342.20.

West Pharmaceutical Services Stock Up 1.4%

WST stock opened at $272.31 on Monday. West Pharmaceutical Services, Inc. has a twelve month low of $187.43 and a twelve month high of $348.90. The company has a quick ratio of 2.18, a current ratio of 2.87 and a debt-to-equity ratio of 0.07. The firm has a market cap of $19.59 billion, a PE ratio of 40.34, a price-to-earnings-growth ratio of 4.21 and a beta of 1.17. The business has a 50 day moving average of $274.12 and a 200 day moving average of $252.50.

West Pharmaceutical Services (NYSE:WST) last released its earnings results on Thursday, October 23rd. The medical instruments supplier reported $1.96 EPS for the quarter, topping the consensus estimate of $1.67 by $0.29. West Pharmaceutical Services had a return on equity of 18.16% and a net margin of 16.29%.The business had revenue of $804.60 million for the quarter, compared to the consensus estimate of $788.42 million. During the same period in the previous year, the company posted $1.85 earnings per share. The company’s revenue for the quarter was up 7.7% compared to the same quarter last year. West Pharmaceutical Services has set its FY 2025 guidance at 7.060-7.110 EPS. On average, research analysts forecast that West Pharmaceutical Services, Inc. will post 6.62 EPS for the current fiscal year.

West Pharmaceutical Services Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, February 4th. Investors of record on Wednesday, January 28th will be given a dividend of $0.22 per share. This represents a $0.88 annualized dividend and a yield of 0.3%. The ex-dividend date of this dividend is Wednesday, January 28th. West Pharmaceutical Services’s dividend payout ratio is 13.04%.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.